Alzheimer’s Drug Development Comparable To Cancer 50 Years Ago, Says Targacept CEO
This article was originally published in The Pink Sheet Daily
Executive Summary
Biomarkers and diagnostic tools must be developed to allow drug manufacturers to target Alzheimer’s disease modification, BioInvestor Forum panelists say.
You may also be interested in...
Medivation Aims For 2010 Approval Of Alzheimer’s Drug Dimebon
The neuroprotectant's novel mechanism of action makes it a good candidate for Alzheimer's disease drug cocktails, CEO Hung says.
Medivation Aims For 2010 Approval Of Alzheimer’s Drug Dimebon
The neuroprotectant's novel mechanism of action makes it a good candidate for Alzheimer's disease drug cocktails, CEO Hung says.
Pfizer Will Examine Genizon Genomic Data For Biomarkers
The firm will use the collaboration as a discovery platform for biomarkers for Alzheimer's disease, ADHD and endometriosis.